All News

Vviloxazine (Qelbree) is a norepinephrine reuptake inhibitor that provides a new treatment option for patients aged 6 to 17 years with ADHD.

Reducing blood pressure is the major determinant of reduction in cardiovascular risk in both young and older patients with hypertension.

Selexipag tablets were first approved by the FDA in 2015 to delay disease progression and reduce the risk of hospitalization for PAH.

Penny pinchers, early arrivals, and more are featured in this month's Pet Peeves.

The FDA has approved the monoclonal antibody mepolizumab as a treatment for patients with chronic rhinosinusitis with nasal polyps.

Sarah Cannon and Pontchartrain Cancer Center will join the esteemed program.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

The study demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the course of the 3-month treatment period.

This month's products include a smart pen cap for insulin dosing, a treatment for benign prostatic hyperplasia, and more.

Lipophilic statins for dyslipidemia penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects.

On average, those who received a flu-like diagnosis changed their cell phone usage behavior 1 day before their diagnosis and the 2 to 4 days afterward.

The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses what led to his interest in the position.

Companies and practitioners should take important steps to protect patients from these mistakes.

Women are significantly less likely than men to undergo coronary artery bypass grafting because of gender disparities in the understanding and treatment of coronary artery disease, research shows.

A decrease in cancer-associated macrophage-like cells was associated with an approximately 300% increase in mean progression-free survival.

Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.

Workflow in the clinic and the pharmacy are critical for the implementation of a new and novel medication therapy, such as cabotegravir-rilpivirine.

Chad Hatfield, PharmD, MHA, BCPS, chief pharmacy officer at UC Davis Medical Center, discusses how data points used in oncology pharmacy practice and how it is collected.

Blood pressure has to be monitored closely in patients diagnosed with stage 1 or 2 hypertension.

FDA approvals of vaccines usually take 10 to 15 years, but the pandemic necessitates emergency action.

A majority of pharmacy departments are presently conducting safety huddles within their teams.

Both researchers received $30,000 to fund projects that demonstrate the ways that new and emerging technologies can assist in the safe and effective use of medications.

Based on their findings, investigators said modifiable risk factors are strongly associated with C-reactive protein levels in patients with coronary artery disease.

The open label trial was available to patients 18 years of age and older with relapsed or refractory DLBCL after 2 or more lines of treatment.

Bezlotoxumab is administered to prevent Clostridium difficile infection from recurring in patients who are receiving treatment for the infection and are at risk for recurrence.

A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.